REPURCHASE OF SHARES IN ASTRAZENECA PLC


 

AstraZeneca PLC announced that, on 24 February 2012, it purchased for cancellation 250,000 ordinary shares of AstraZeneca PLC at a price of 2878 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,276,958,144.

A C N Kemp

Company Secretary

27 February 2012

 

 

Tags:

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com